Laurus Labs (BOM:540222) Beneish M-Score: -2.68 (As of Jun. 30, 2026)


BOM:540222 Laurus Labs Ltd BOM:540222
66 GF Score
Price ₹1,502.90
GF Value ₹697.80
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Laurus Labs Beneish M-Score?

Laurus Labs BOM:540222 +3.61% 66 Beneish M-Score is -2.68 as of Jun. 30, 2026. GuruFocus rates BOM:540222 with a GF Score™ of 66/100 and a GF Value™ of ₹697.80 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 908 Drug Manufacturers companies, Laurus Labs ranks better than 66.41% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.68 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Laurus Labs's Beneish M-Score or its related term are showing as below:

BOM:540222' s Beneish M-Score Range Over the Past 10 Years
Min: -2.85   Med: -2.58   Max: -1.47
Current: -2.68

During the past 13 years, the highest Beneish M-Score of Laurus Labs was -1.47. The lowest was -2.85. And the median was -2.58.


Laurus Labs Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Laurus Labs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laurus Labs Beneish M-Score Chart

Laurus Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.56 -2.35 -2.79 -2.39 -2.68

Laurus Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.39 0.00 0.00 0.00 -2.68

BOM:540222 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laurus Labs Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Laurus Labs's Beneish M-Score falls into.


BOM:540222
66GF Score
Laurus Labs Ltd BOM:540222
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laurus Labs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Laurus Labs for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8833+0.528 * 0.9153+0.404 * 1.0374+0.892 * 1.2203+0.115 * 1.0117
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7927+4.679 * -0.069898-0.327 * 0.9113
=-2.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹21,999 Mil.
Revenue was ₹67,212 Mil.
Gross Profit was ₹39,576 Mil.
Total Current Assets was ₹48,292 Mil.
Total Assets was ₹105,112 Mil.
Property, Plant and Equipment(Net PPE) was ₹48,792 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹4,801 Mil.
Selling, General, & Admin. Expense(SGA) was ₹2,431 Mil.
Total Current Liabilities was ₹36,354 Mil.
Long-Term Debt & Capital Lease Obligation was ₹7,228 Mil.
Net Income was ₹8,888 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹16,235 Mil.
Total Receivables was ₹20,409 Mil.
Revenue was ₹55,079 Mil.
Gross Profit was ₹29,685 Mil.
Total Current Assets was ₹43,323 Mil.
Total Assets was ₹93,356 Mil.
Property, Plant and Equipment(Net PPE) was ₹43,160 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹4,301 Mil.
Selling, General, & Admin. Expense(SGA) was ₹2,513 Mil.
Total Current Liabilities was ₹35,397 Mil.
Long-Term Debt & Capital Lease Obligation was ₹7,078 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(21999.3 / 67212.3) / (20409.2 / 55078.6)
=0.327311 / 0.370547
=0.8833

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(29684.5 / 55078.6) / (39576.4 / 67212.3)
=0.538948 / 0.588827
=0.9153

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (48292.1 + 48792.2) / 105111.9) / (1 - (43323.2 + 43159.6) / 93355.7)
=0.076372 / 0.073621
=1.0374

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=67212.3 / 55078.6
=1.2203

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4300.9 / (4300.9 + 43159.6)) / (4800.5 / (4800.5 + 48792.2))
=0.090621 / 0.089574
=1.0117

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2431.2 / 67212.3) / (2513.2 / 55078.6)
=0.036172 / 0.045629
=0.7927

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((7228.3 + 36354.3) / 105111.9) / ((7077.7 + 35397.2) / 93355.7)
=0.414631 / 0.454979
=0.9113

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(8887.9 - 0 - 16235) / 105111.9
=-0.069898

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Laurus Labs has a M-score of -2.68 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.68 mean?
Laurus Labs (BOM:540222) has a Beneish M-Score of -2.68 as of Jun. 30, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Laurus Labs and its competitors. According to the industry distribution chart, Laurus Labs ranks #305 out of 908 companies in the Drug Manufacturers industry, placing it in the top 33.6%.
Is Laurus Labs' Beneish M-Score too high?
Laurus Labs' current Beneish M-Score is -2.68. Based on the distribution chart, Laurus Labs ranks #305 out of 908 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laurus Labs ranks #305 out of 908 companies for Beneish M-Score. This puts Laurus Labs in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Laurus Labs and its competitors. Laurus Labs's current Beneish M-Score is -2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹697.80, compared to a current price of ₹1,502.90 — trading 115.4% above its estimated fair value. The current Beneish M-Score is -2.68. Laurus Labs' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current Beneish M-Score is -2.68 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laurus Labs (BOM:540222) Overvalued in 2026?

Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued. The current stock price of ₹1,502.90 is trading 115.4% above its estimated GF Value™ of ₹697.80. GuruFocus considers Laurus Labs to be Significantly Overvalued.

Key valuation signals for BOM:540222:

  • Beneish M-Score: -2.68
  • GF Value™: ₹697.80 vs. price of ₹1,502.90 (115.4% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Laurus Labs Business Description

Other Exchanges LAURUSLABS:India
Address Road No.1, Jubilee Hills, Plot No.103, Hyderabad, TG, IND, 500033
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score

Get the complete analysis for BOM:540222

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,502.90
Price
₹697.80
GF Value